CIK 0000730272
- Large accelerated filer
REPLIGEN CORP
Sign in to watch- Ticker
- RGEN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 042729386
- Phone
- +1 781-449-9560
- Business address
- 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,976,580
- in 4 filings, $5.0M under 10b5-1 plans
Net −$4,976,580. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-05-13 | Snodgres Jon Chief Financial Officer | Sale | −1,612 | $128.70 | $207K | 38,486 |
| 2020-05-13 | Snodgres Jon Chief Financial Officer | Sale | −1,700 | $130.20 | $221K | 36,786 |
| 2020-05-13 | Snodgres Jon Chief Financial Officer | Sale | −3,013 | $131.38 | $396K | 33,773 |
| 2020-05-13 | Snodgres Jon Chief Financial Officer | Sale | −846 | $132.37 | $112K | 32,927 |
| 2020-05-13 | Snodgres Jon Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) | −3,170 | 0 | ||
| 2020-05-13 | Snodgres Jon Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) | −9,024 | 3,086 | ||
| 2020-05-13 | KURIYEL RALF Senior VP, R&D | Exercise or conversion | +6,000 | $33.05 | $198K | 32,524 |
| 2020-05-13 | KURIYEL RALF Senior VP, R&D | Exercise or conversion | +2,000 | $33.87 | $68K | 34,524 |
| 2020-05-13 | KURIYEL RALF Senior VP, R&D | Sale | −1,612 | $126.88 | $205K | 32,912 |
| 2020-05-13 | KURIYEL RALF Senior VP, R&D | Sale | −6,293 | $128.02 | $806K | 26,619 |
| 2020-05-13 | KURIYEL RALF Senior VP, R&D | Sale | −95 | $128.55 | $12K | 26,524 |
| 2020-05-13 | KURIYEL RALF Senior VP, R&D | Exercise or conversion · Stock Option (Right to Buy) | −6,000 | 4,000 | ||
| 2020-05-13 | KURIYEL RALF Senior VP, R&D | Exercise or conversion · Stock Option (Right to Buy) | −2,000 | 10,850 | ||
| 2020-04-22 | BARTHELEMY NICOLAS Director | Exercise or conversion | +1,652 | $42.07 | $69K | 5,725 |
| 2020-04-22 | BARTHELEMY NICOLAS Director | Sale | −2,688 | $109.99 | $296K | 3,037 |
| 2020-04-22 | BARTHELEMY NICOLAS Director | Exercise or conversion · Stock Option (Right to Buy) | −1,652 | 0 | ||
| 2020-04-21 | DAWES KAREN A Director | Exercise or conversion | +11,800 | $3.30 | $39K | 120,834 |
| 2020-04-21 | DAWES KAREN A Director | Exercise or conversion · Stock Option (Right to Buy) | −11,800 | 0 | ||
| 2020-04-21 | DAWES KAREN A Director | Exercise or conversion | +11,800 | $3.30 | $39K | 120,834 |
| 2020-04-21 | DAWES KAREN A Director | Exercise or conversion · Stock Option (Right to Buy) | −11,800 | 0 |
Page 36 of 42 · 832 trades